

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>VAGELOS P ROY</u> (Last) (First) (Middle) <u>777 OLD SAW MILL RIVER ROAD</u> (Street) <u>TARRYTOWN NY 10591</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>REGENERON PHARMACEUTICALS INC</u> [<u>REGN</u>]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chairman of the Board</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>09/18/2013</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	09/18/2013		M ⁽¹⁾		312,500	A	\$13	378,259	D	
Common Stock	09/18/2013		F ⁽¹⁾		13,346	D	\$304.38	364,913	D	
Common Stock	09/18/2013		F ⁽¹⁾		153,798	D	\$304.38	211,115	D	
Common Stock	09/19/2013		s ⁽¹⁾		61,159	D	\$300.34 ⁽²⁾	149,956	D	
Common Stock	09/19/2013		s ⁽¹⁾		21,179	D	\$301.42 ⁽³⁾	128,777	D	
Common Stock	09/19/2013		s ⁽¹⁾		10,742	D	\$302.86 ⁽⁴⁾	118,035	D	
Common Stock	09/19/2013		s ⁽¹⁾		6,780	D	\$303.49 ⁽⁵⁾	111,255	D	
Common Stock	09/19/2013		s ⁽¹⁾		11,286	D	\$304.8 ⁽⁶⁾	99,969	D	
Common Stock	09/19/2013		s ⁽¹⁾		13,126	D	\$305.28 ⁽⁷⁾	86,843	D	
Common Stock	09/19/2013		s ⁽¹⁾		5,084	D	\$306.46 ⁽⁸⁾	81,759	D	
Common Stock	09/19/2013		s ⁽¹⁾		4,500	D	\$308.4 ⁽⁹⁾	77,259	D	
Common Stock	09/19/2013		s ⁽¹⁾		2,600	D	\$309.84 ⁽¹⁰⁾	74,659	D	
Common Stock	09/19/2013		s ⁽¹⁾		8,900	D	\$310.18 ⁽¹¹⁾	65,759	D	
Common Stock	07/05/2013		G	V	921	D	\$0.0	159,267	I	by CLAT
Common Stock								73,597	I	by GRAT
Common Stock								2,352	I	By 401(k) Plan
Common Stock								15,162	I	by GRAT
Common Stock								3	I	by GRAT
Common Stock								114,750	I	by Spouse as Trustee
Common Stock								1,203	I	by trust for grandch ⁽¹²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non-Qualified Stock Option (right to buy)	\$13	09/18/2013		M ⁽¹⁾			312,500	(13)	12/15/2013	Common Stock	312,500	\$0.0	0	D	

Explanation of Responses:

- Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- Represents volume-weighted average price of sales of 61,159 shares of Company stock on September 19, 2013 at prices ranging from \$300.00 to \$300.95. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price.
- Represents volume-weighted average price of sales of 21,179 shares of Company stock on September 19, 2013 at prices ranging from \$301.00 to \$301.74. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price.
- Represents volume-weighted average price of sales of 10,742 shares of Company stock on September 19, 2013 at prices ranging from \$302.56 to \$302.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price.
- Represents volume-weighted average price of sales of 6,780 shares of Company stock on September 19, 2013 at prices ranging from \$303.07 to \$303.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price.
- Represents volume-weighted average price of sales of 11,286 shares of Company stock on September 19, 2013 at prices ranging from \$304.19 to \$304.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price.
- Represents volume-weighted average price of sales of 13,126 shares of Company stock on September 19, 2013 at prices ranging from \$305.00 to \$300.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price.
- Represents volume-weighted average price of sales of 5,084 shares of Company stock on September 19, 2013 at prices ranging from \$306.10 to \$306.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price.
- Represents volume-weighted average price of sales of 4,500 shares of Company stock on September 19, 2013 at prices ranging from \$308.05 to \$308.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price.
- Represents volume-weighted average price of sales of 2,600 shares of Company stock on September 19, 2013 at prices ranging from \$309.09 to \$309.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price.
- Represents volume-weighted average price of sales of 8,900 shares of Company stock on September 19, 2013 at prices ranging from \$310.00 to \$310.51. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 19, 2013 at each separate price.
- By a trust for the benefit of certain grandchildren of the reporting person, of which the reporting person and/or the spouse of the reporting person is trustee.
- The stock option becomes 100% exercisable one year after the date of grant.

By: /s/*Douglas McCorkle as
attorney-in-fact For: /s/*P. Roy. 09/20/2013
Vagelos

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Leonard Schleifer, , Beverly Dubs, Stuart Kolinski, Murray Goldberg, and Douglas McCorkle signing singly, the undersigned's true and lawful attorney-in-fact to:

- (1) execute for and on behalf of the undersigned in the undersigned's capacity as a director of Regeneron Pharmaceuticals, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 16th day of September, 2005.

**/s/P. Roy Vagelos

Signature

P, Roy Vagelos

Print Name